Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD039
MIFTS: 35

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Adenocarcinoma

About this section

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 71
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 54

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3711
NCIt 49 C4032
SNOMED-CT 67 255110003
UMLS 71 C0279682
Sources

Summaries for Bladder Adenocarcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to hepatoid adenocarcinoma and bladder clear cell adenocarcinoma, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways is Primary Focal Segmental Glomerulosclerosis FSGS. The drugs Fluorouracil and Alkylating Agents have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and colon.

Sources

Related Diseases for Bladder Adenocarcinoma

About this section

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 275)
# Related Disease Score Top Affiliating Genes
1 hepatoid adenocarcinoma 30.6 KRT7 CDX2
2 bladder clear cell adenocarcinoma 30.3 UPK3A KRT7 KRT20 CDX2 AMACR
3 adenocarcinoma 30.1 KRT7 KRT20 KLK3 CTNNB1 CDX2
4 appendix adenocarcinoma 29.9 KRT7 KRT20 CDX2
5 papilloma 29.9 PCNA KRT7 KRT20
6 linitis plastica 29.8 KRT7 KRT20 CDX2
7 hydronephrosis 29.7 UPK3A KRT7 KLK3
8 villous adenoma 29.7 KRT20 KLK3 CDX2
9 nephrogenic adenoma 29.6 KRT7 KLK3 AMACR
10 bladder cancer 29.6 UPK3A UCA1 MKI67 KRT20 CTNNB1
11 adenocarcinoma in situ 29.6 KRT7 KRT20 CDX2
12 mucinous cystadenocarcinoma 29.6 KRT7 KRT20
13 inverted papilloma 29.6 PCNA MKI67 KRT7 KRT20
14 colorectal adenocarcinoma 29.5 KRT7 KRT20 CTNNB1 CDX2
15 urethra adenocarcinoma 29.4 KLK3 AMACR
16 signet ring cell adenocarcinoma 29.3 KRT7 KRT20 CTNNB1 CDX2
17 rectum adenocarcinoma 29.3 KRT7 KRT20 CTNNB1 CDX2
18 tubular adenocarcinoma 29.3 KRT7 KRT20 CTNNB1 CDX2
19 cystitis 29.3 UPK3A KRT7 KRT20 CDX2
20 cystitis cystica 29.2 KRT7 KRT20 KLK3 CDX2
21 mucinous adenocarcinoma 29.0 KRT7 KRT20 CDX2 AMACR
22 gastric adenocarcinoma 29.0 KRT7 KRT20 GATA3 CTNNB1 CDX2
23 adenoma 29.0 MKI67 KRT7 KRT20 CTNNB1 CDX2
24 suppression of tumorigenicity 12 28.7 KRT7 KLK3 CTNNB1 AMACR
25 clear cell adenocarcinoma 28.5 KRT7 KRT20 KLK3 AMACR
26 transitional cell carcinoma 28.5 UPK3A MKI67 KRT7 KRT20 KLK3 CTNNB1
27 lung cancer susceptibility 3 28.3 KRT7 KRT20 CTNNB1 CDX2 AMACR
28 endometrial cancer 27.9 UCA1 PCNA MKI67 KRT7 KRT20 KLK3
29 glandular cystitis 26.9 UPK3A UCA1 KRT7 KRT20 KLK3 CTNNB1
30 breast cancer 26.8 UCA1 PCNA MKI67 KRT7 KRT20 KLK3
31 pelvic lipomatosis 11.3
32 bladder signet ring cell adenocarcinoma 11.3
33 bladder colonic type adenocarcinoma 11.3
34 bladder urachal adenocarcinoma 11.3
35 bladder tubulo-cystic clear cell adenocarcinoma 11.3
36 bladder papillary clear cell adenocarcinoma 11.3
37 bladder hepatoid adenocarcinoma 11.3
38 embryonal sarcoma 10.4 MKI67 CTNNB1
39 polymorphous low-grade adenocarcinoma 10.4 MKI67 CTNNB1
40 oral leukoplakia 10.4 PCNA MKI67
41 leukoplakia 10.4 PCNA MKI67
42 gallbladder adenoma 10.3 KRT7 CTNNB1
43 goblet cell carcinoid 10.3 KRT20 CTNNB1
44 necrotizing sialometaplasia 10.3 MKI67 KRT7
45 small intestine adenocarcinoma 10.3 CTNNB1 CDX2
46 ovary neuroendocrine neoplasm 10.3 KRT7 CDX2
47 anal canal paget's disease 10.3 KRT7 CDX2
48 anal paget's disease 10.3 KRT7 CDX2
49 anal gland adenocarcinoma 10.3 KRT7 CDX2
50 ureter adenocarcinoma 10.3 KRT7 CDX2

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma
Sources

Symptoms & Phenotypes for Bladder Adenocarcinoma

About this section

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria
Sources

Drugs & Therapeutics for Bladder Adenocarcinoma

About this section

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3 51-21-8 3385
2 Alkylating Agents Phase 3
3 Mitomycins Phase 3
4
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
5
Bevacizumab Approved, Investigational Phase 2 216974-75-3
6
Ifosfamide Approved Phase 2 3778-73-2 3690
7
leucovorin Approved Phase 2 58-05-9 6006 143
8
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
9
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
10
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
11
Daunorubicin Approved Phase 2 20830-81-3 30323
12
Durvalumab Approved, Investigational Phase 2 1428935-60-7
13
Vinblastine Approved Phase 2 865-21-4 241903 13342
14
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
15
Ipilimumab Approved Phase 2 477202-00-9
16
nivolumab Approved Phase 2 946414-94-4
17
Gemcitabine Approved Phase 2 95058-81-4 60750
18
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
19
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
20 Piritrexim Investigational Phase 2 72732-56-0
21
Rubitecan Investigational Phase 2 91421-42-0
22
Camptothecin Experimental Phase 2 7689-03-4
23 Angiogenesis Inhibitors Phase 2
24
Isophosphamide mustard Phase 2 0
25 topoisomerase I inhibitors Phase 2
26 Antineoplastic Agents, Immunological Phase 2
27 Vitamin B Complex Phase 2
28 Folic Acid Antagonists Phase 2
29 Folate Phase 2
30 Vitamin B9 Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Anti-Bacterial Agents Phase 2
33 Antibodies Phase 2
34 Antibodies, Monoclonal Phase 2
35 Immunoglobulins Phase 2
36
Liposomal doxorubicin Phase 2 31703
37 Dermatologic Agents Phase 2
38 Antirheumatic Agents Phase 2
39 Immunologic Factors Phase 2
40 Anti-Infective Agents Phase 2
41 Immunosuppressive Agents Phase 2
42 Antiviral Agents Phase 2
43 Antimetabolites Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Tubulin Modulators Phase 2
46 Antimitotic Agents Phase 2
47
Pancrelipase Approved, Investigational Phase 1 53608-75-6
48
Sargramostim Approved, Investigational Phase 1 83869-56-1, 123774-72-1
49
Metronidazole Approved Phase 1 443-48-1 4173
50 Molgramostim Investigational Phase 1 99283-10-0

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 2X2 Factorial Randomized Phase III Study Comparing Standard Versus Reduced Volume Radiotherapy With and Without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
2 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
3 A Multicenter Phase II Study of Gemcitabine, Capecitabine and Bevacizumab for Locally Advanced or Metastatic Adenocarcinoma of the Gall Bladder or Biliary Ducts. Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
4 PHASE II STUDY OF PIRITREXIM IN ADVANCED CARCINOMA OF THE UROTHELIUM Completed NCT00002914 Phase 2 piritrexim
5 Phase II Trial of Paclitaxel, Cisplatin and Ifosfamide in Patients With Advanced Urothelial Tumors Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
6 Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Advanced/Metastatic Urothelial Tract Tumors Completed NCT00006026 Phase 2 rubitecan
7 A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder Recruiting NCT03747419 Phase 2 Avelumab
8 Phase 2 Open Label Study of Durvalumab With Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
9 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
10 Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (and in a Cohort of Patients Younger Than 60 Years) Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
11 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
12 Phase I Study of Intravesical Recombinant Fowlpox - GM-CSF (rF-GM-CSF) and/or Recombinant Fowlpox-TRICOM (rF-TRICOM) in Patients With Bladder Carcinoma Scheduled for Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Sources

Genetic Tests for Bladder Adenocarcinoma

About this section
Sources

Anatomical Context for Bladder Adenocarcinoma

About this section

MalaCards organs/tissues related to Bladder Adenocarcinoma:

40
Prostate, Lung, Colon, Skin, Lymph Node, Liver, Breast
Sources

Publications for Bladder Adenocarcinoma

About this section

Articles related to Bladder Adenocarcinoma:

(show top 50) (show all 152)
# Title Authors PMID Year
1
Clinicopathologic features and utility of immunohistochemical markers in signet-ring cell adenocarcinoma of the bladder. 61 54
18789486 2009
2
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 54 61
18670358 2008
3
[Expression of CDX2 in urinary bladder and urethra lesions]. 61 54
15074058 2004
4
Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. 54 61
11684954 2001
5
Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases. 54 61
10658909 2000
6
Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma. 61 54
9522212 1998
7
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. 61
32520749 2020
8
Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma. 61
31740332 2020
9
HER-2/neu over expression in gall bladder adenocarcinoma: A quest for potential therapeutic target. 61
32317518 2020
10
Comparative genomic profiling of glandular bladder tumours. 61
32198650 2020
11
Coexistent Dedifferentiated Endometrioid Carcinoma of the Uterus and Adenocarcinoma of the Bladder in Lynch Syndrome: Case Report and Review of the Literature. 61
32167968 2020
12
Mutational Profile Using Next-Generation Sequencing May Aid in the Diagnosis and Treatment of Urachal Adenocarcinoma. 61
31496327 2020
13
Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring HER2 Amplification and S310F Mutation Discovered by Next-Generation Sequencing: A Case Report. 61
32547059 2020
14
Bile spillage and incidental gall bladder adenocarcinoma. 61
31929997 2019
15
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. 61
31666198 2019
16
Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma. 61
31876604 2019
17
Aggressive course in a patient with mucin-producing urothelial-type adenocarcinoma of the prostate: A case report and review of the literature. 61
32027595 2019
18
Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. 61
31395362 2019
19
A report of orbital metastasis from a urinary bladder adenocarcinoma. 61
31332150 2019
20
Mimickers of urothelial neoplasia. 61
30380401 2019
21
Primary signet-ring cell carcinoma of the urinary bladder: A report of two cases. 61
31535712 2019
22
Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression. 61
31317053 2019
23
Non-urothelial carcinomas of the bladder. 61
30565306 2019
24
Treating bladder adenocarcinoma. 61
30687599 2018
25
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. 61
31049173 2018
26
microRNA‑145 modulates migration and invasion of bladder cancer cells by targeting N‑cadherin. 61
29693148 2018
27
Primary bladder adenocarcinoma: Case report with long-term follow-up. 61
29785373 2018
28
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. 61
27048257 2018
29
Squamous Cell and Adenosquamous Carcinoma of Gall Bladder: a Clinicopathological Study of 8 Cases Isolated in 94 Cancers. 61
29203990 2017
30
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. 61
28548125 2017
31
Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features - multiple primaries versus metastatic neoplasms: a case report. 61
28494807 2017
32
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. 61
28511402 2017
33
Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review. 61
28056456 2017
34
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. 61
27427223 2016
35
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature. 61
27381065 2016
36
Mucinous adenocarcinoma of the bladder: A case report and review of the literature. 61
27703678 2016
37
Cutaneous metastasis: An unusual presenting feature of urologic malignancies. 61
27453667 2016
38
Intestinal metaplasia of the bladder in 89 patients: a study with emphasis on long-term outcome. 61
27267922 2016
39
[Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review]. 61
27266688 2016
40
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. 61
27081650 2016
41
Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder. 61
26463756 2016
42
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. 61
26955660 2016
43
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. 61
27006847 2016
44
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. 61
27288750 2016
45
[A Case of Bladder Adenocarcinoma with Rectal Metastasis]. 61
26805326 2015
46
Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. 61
25930983 2015
47
Exfoliative erythroderma as a paraneoplastic presentation of adenocarcinoma of the gallbladder. 61
25830047 2015
48
Gall bladder Adenocarcinoma in a Young Girl. 61
26139973 2015
49
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. 61
24281125 2015
50
En Bloc Robot-assisted Laparoscopic Partial Cystectomy, Urachal Resection, and Pelvic Lymphadenectomy for Urachal Adenocarcinoma. 61
26029004 2015
Sources

Variations for Bladder Adenocarcinoma

About this section
Sources

Expression for Bladder Adenocarcinoma

About this section
Search GEO for disease gene expression data for Bladder Adenocarcinoma.
Sources

Pathways for Bladder Adenocarcinoma

About this section

Pathways related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.67 PCNA MKI67 CTNNB1
Sources

GO Terms for Bladder Adenocarcinoma

About this section

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.33 UPK3A GATA3 CTNNB1
2 anterior/posterior axis specification GO:0009948 9.32 CTNNB1 CDX2
3 cell fate determination GO:0001709 9.26 GATA3 CTNNB1
4 regulation of epithelial cell differentiation GO:0030856 8.96 GATA3 CTNNB1
5 regulation of nephron tubule epithelial cell differentiation GO:0072182 8.62 GATA3 CTNNB1

Molecular functions related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 8.8 PCNA MKI67 CTNNB1
Sources

Sources for Bladder Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....